Peer Review History
| Original SubmissionJune 17, 2020 |
|---|
|
PONE-D-20-18576 Why women with breast cancer presented late to health care facility in North-western Ethiopia? A qualitative study PLOS ONE Dear Dr. Tesfaw, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Oct 26 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Alvaro Galli Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please include a copy of the interview guide used in the study, in both the original language and English, as Supporting Information, or include a citation if it has been published previously." 3. Please amend your current ethics statement to address the following concerns: Please explain why written consent was not obtained, how you recorded/documented participant consent, and if the ethics committees/IRBs approved this consent procedure. 4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: It is a very good effort to describe the reasons underlying late presentation of breast cancer in North Western Ethiopia. Some genuine reasons have been presented as to why the breast cancer patients approach late to the health care facilities in that part of the country. However, the data of only 14 breast cancer patients spanned over the record of 1-2 months is not insufficient for any statistically significant information. I would suggest the authors to include as much number of patients as possible to report a significant data for such type of study. Reviewer #2: Background: 1. This is a qualitative research design that examined the experiences of 14 women who delayed seeking medical care for breast cancer symptoms and were diagnosed with advanced breast cancer. I think the manuscript would be more interesting if the authors could expand the introduction section to include more information and background related to cultural factors that impact healthcare seeking of women experiencing breast cancer symptoms. Some of this literature could be compared to other cultures to give the reader more of an idea how the health care seeking behavior in Ethiopia is different or similar to other countries/cultures 2. Most up-to-date data sets should be used throughout the paper. 1st paragraph of the background should use most recent GLOBOCAN data (2018 Factsheet)-cite specific figures. 3. “Breast cancer is the most prevalent cancer in African women, although its incidence is lower compared to high-income countries”. Please provide evidence for this statement. 4. It would be good to have information regarding breast cancer’s incidence and mortality rates in Ethiopia and then compare it other developed countries to show the disproportionate burden of the disease. 5. “In Ethiopia, According to the Addis Ababa……...”, please change ‘’According’’ to according. 6. “Advanced stage and large tumour size at diagnosis are associated with decreased survival”. Please cite evidence for this statement. 7. …….. “A study conducted in 2011 among breast cancer patients in Ethiopia also revealed 47.8% of study participants were nothing know about breast cancer and never heard of the - 5 - disease at all [14]” Please make this claim clear to readers. 8. It would be very effective in addressing delay presentations if authors also compared developed western health care systems that have recently reported on presentations of breast cancer. It is also necessary to include information about the current breast cancer screening guidelines in Ethiopia. Because decreasing delay presentation and breast cancer mortality rate is also dependant on the availability of appropriate screening and timely treatment of breast cancer, some information about the current screening, diagnosis and treatment of breast cancer in Ethiopia would be very helpful here as well. Methods Study area and approach The study setting is well described, however, there is no mention on the study design. Authors are advised to clearly state the study’s design, the rational for choosing the design whiles citing evidence to support it. Participants of the in-depth interview and recruitment procedures This section needs further description to aid in future transferability and replication of the study. The target population has been specified but the criteria for inclusion and exclusion are missing. Please add them. The participants recruitment procedure has not been described. Please provide detail description of how the study participants were recruited and enrolled into the study. Data Collection Procedure 1. How were the participants sampled? Please include this. 2. Please what informed the selection of six and eight patients from the respective hospitals involved in the study 3. Please how did the authors determined patients with serious illness and communication difficulty. It will be very advisable for authors to clearly specify the eligibility criteria. 4. The interview guide was developed through literature review. Please describe the development process. How did the authors ascertained its reliability (thus, the ability to answer the study objective(s)? Were the guiding questions piloted? If yes, what was the outcome? Please include a type of semi-structured questions asked. 5. Please indicate the experience/expertise of researcher who conducted qualitative data collection. 6. There is no mention on how the participants were contacted. Who did the first contact? How were the interview appointments scheduled? Date, time, venue 7. Please calculate the average interview time. 8. What was the interview language? 9. How did the authors determined that the information has reached saturation? 10. Please describe how participants emotional reactions were addressed in the course of sharing their experiences. 11. It would be very helpful for the authors to provide detail on how data saturation was achieved since two individuals collected the data. Please indicate the number of interviews conducted by each interviewer. 12. Did each interviewer focused on one hospital or they conducted the interviews across the hospitals involved in the study. 13. Please describe how the anonymity and confidentiality were maintained in the data collection process. 14. Please clarify whether there was any change to the interview guide as the authors went along; often in qualitative methodologies, there is an iterative process where the questions are subsequently added or shaped based on the data that emerges prior to determining saturation was achieved. 15. How was the data managed? Data Analysis procedure 1. Please who transcribed the data? Interviewers or different people? 2. Verbatim transcription in what language. Please describe the process of the translation into English and the background of the translators. 3. What analysis technique was employed for the data analysis. There is inconsistency on data analysis technique in the abstract and in this section. Please align. Authors need to describe specifically how they conduct analysis of this study. 16. Who analyzed the data? Please indicate the experience/expertise of researcher who conducted qualitative data analysis. 17. I suggest a reference to the open code software version 4.02. Please describe the analysis process sufficient detailed, so the readers have a clear understanding of how the analysis was carried out. The analysis is not clearly described i.e how text was categorized and developed to themes. Please, give some more details about the data analysis. 18. There is an obvious bias that is integrated into the qualitative analysis if interviewee and data analyst differ. The authors should explicitly explain whether and how this was addressed in their qualitative investigation, and speculate as to how this may have biased the results. They may also want to comment on whether both men and women were involved in the interpretation of findings as the research specifically focuses on women. Ethics consideration Please provide the ethical approval number Rigor/trustworthiness There is no mention on the study rigor and this is a major flaw of the study. How did the authors ensured the trustworthiness of this qualitative study? Result 1. Under the data collection procedure, the authors claim they conducted in-depth interview on 14 newly diagnosed breast cancer patients who had self-reported delay of more than three month from their initial symptom recognition until their first health care visit. Now, in the results section, the authors report that majority of the patients have delay of more than six month from their initial visit. Please this is a confusing conflicting statement indicative of inconsistency and flaw. Please address this. 2. It would be easier for readers to appreciate the findings if authors specify the main themes and their sub-themes. Putting them in a table may be helpful. Table 2 is depicting the codes assigned to the recurring phrases from the participants’ narrations and not the main findings (main theme and sub-themes). 3. The result is described with a several quotations. Some of the quotations stands alone, so it would therefore facilitate for the reader if you could insert some short sentences in between the quotations to connect the paragraphs with each other. 4. In the "themes" section, there are quotes that do not demonstrate the claim/point made. Authors need to look closely to ensure appropriate quotes are used. 5. When there are more citations than authorial text, the analysis is usually incomplete, which I find in this paper. Why are only a few participants quotes included? 6. These results do not differ significantly from the general late presentation of breast cancer literature. They do, however, highlight some patient-related mediators, some of which may be difficult to understand without clarity around the early detection practices and why women would wait for over six months after symptom discovery and appraisal. The novel contributions of this study may be strengthened by providing further background around early detection and diagnostic practices in Ethiopia (e.g. lack of screening facilities, lack meaningful diagnostic facilities, lack of aid from social networks), or on specifically discussing in the discussion how poverty, stigma, fear and limited access to quality care have directly affected these women. 7. The author's results may be easier to interpret if they begin their results section in commenting on the demanding patient mediated factors that is highlighted in the results under the main themes and sub-themes. As it stands now, it seems the main themes had no sub-themes. Discussion: As a reader, I am somewhat surprised that all participants had similar experiences and that there are no specific experiences that may have differed between participants. This makes me wonder if the sample was not generalizable, or if these themes do truly apply to all women presenting late with breast cancer symptoms in Ethiopia. This should be discussed and explicitly addressed with the author's reflections A clinical implications section would be helpful to help guide healthcare workers who are interacting with this population. Language Please look through your language and make improvements, for instance long sentences. Attention should also be paid to editing as there are some grammatical errors throughout the paper. Thank you. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Shahid Mahmood Baig, Professor, Head of Health Biotechnology and Group Leader of Human Molecular Genetics at National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad 38000, PAKISTAN Reviewer #2: Yes: ADWOA BEMAH Boamah Mensah [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Why women with breast cancer presented late to health care facility in North-western Ethiopia? A qualitative study PONE-D-20-18576R1 Dear Dr. Tesfaw, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Alvaro Galli Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors have addressed all the comments adequately. The manuscript is recommended in its present form provided a very careful proof reading is done. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Shahid Mahmood Baig |
| Formally Accepted |
|
PONE-D-20-18576R1 Why women with breast cancer presented late to health care facility in North-west Ethiopia? A qualitative study Dear Dr. Tesfaw: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Alvaro Galli Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .